van den Pol Anthony N, Mao Guochao, Chattopadhyay Anasuya, Rose John K, Davis John N
Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA
Department of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut, USA.
J Virol. 2017 Feb 28;91(6). doi: 10.1128/JVI.02154-16. Print 2017 Mar 15.
Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses that include genes from other viruses show promise as vaccines and oncolytic viruses. However, the critical safety concern is the neurotropic nature conveyed by the VSV glycoprotein. VSVs that include the VSV glycoprotein (G) gene, even in most recombinant attenuated strains, can still show substantial adverse or lethal actions in the brain. Here, we test 4 chimeric viruses in the brain, including those in which glycoprotein genes from Nipah, chikungunya (CHIKV), and influenza H5N1 viruses were substituted for the VSV glycoprotein gene. We also test a virus-like vesicle (VLV) in which the VSV glycoprotein gene is expressed from a replicon encoding the nonstructural proteins of Semliki Forest virus. VSVΔG-CHIKV, VSVΔG-H5N1, and VLV were all safe in the adult mouse brain, as were VSVΔG viruses expressing either the Nipah F or G glycoprotein. In contrast, a complementing pair of VSVΔG viruses expressing Nipah G and F glycoproteins were lethal within the brain within a surprisingly short time frame of 2 days. Intranasal inoculation in postnatal day 14 mice with VSVΔG-CHIKV or VLV evoked no adverse response, whereas VSVΔG-H5N1 by this route was lethal in most mice. A key immune mechanism underlying the safety of VSVΔG-CHIKV, VSVΔG-H5N1, and VLV in the adult brain was the type I interferon response; all three viruses were lethal in the brains of adult mice lacking the interferon receptor, suggesting that the viruses can infect and replicate and spread in brain cells if not blocked by interferon-stimulated genes within the brain. Vesicular stomatitis virus (VSV) shows considerable promise both as a vaccine vector and as an oncolytic virus. The greatest limitation of VSV is that it is highly neurotropic and can be lethal within the brain. The neurotropism can be mostly attributed to the VSV G glycoprotein. Here, we test 4 chimeric viruses of VSV with glycoprotein genes from Nipah, chikungunya, and influenza viruses and nonstructural genes from Semliki Forest virus. Two of the four, VSVΔG-CHIKV and VLV, show substantially attenuated neurotropism and were safe in the healthy adult mouse brain. VSVΔG-H5N1 was safe in the adult brain but lethal in the younger brain. VSVΔG Nipah F+G was even more neurotropic than wild-type VSV, evoking a rapid lethal response in the adult brain. These results suggest that while chimeric VSVs show promise, each must be tested with both intranasal and intracranial administration to ensure the absence of lethal neurotropism.
包含来自其他病毒基因的基于重组水疱性口炎病毒(VSV)的嵌合病毒有望成为疫苗和溶瘤病毒。然而,关键的安全问题是VSV糖蛋白所具有的嗜神经性。包含VSV糖蛋白(G)基因的VSV,即使在大多数重组减毒株中,在脑中仍可表现出显著的不良或致死作用。在此,我们在脑中测试了4种嵌合病毒,包括那些用尼帕病毒、基孔肯雅病毒(CHIKV)和甲型H5N1流感病毒的糖蛋白基因替代VSV糖蛋白基因的病毒。我们还测试了一种病毒样囊泡(VLV),其中VSV糖蛋白基因由编码塞姆利基森林病毒非结构蛋白的复制子表达。VSVΔG-CHIKV、VSVΔG-H5N1和VLV在成年小鼠脑中都是安全的,表达尼帕病毒F或G糖蛋白的VSVΔG病毒也是如此。相比之下,一对互补的表达尼帕病毒G和F糖蛋白的VSVΔG病毒在短短2天的时间内就在脑内致死。在出生后第14天的小鼠中鼻内接种VSVΔG-CHIKV或VLV未引起不良反应,而通过此途径接种的VSVΔG-H5N1在大多数小鼠中是致死的。VSVΔG-CHIKV、VSVΔG-H5N1和VLV在成年脑中安全的关键免疫机制是I型干扰素反应;这三种病毒在缺乏干扰素受体的成年小鼠脑中都是致死的,这表明如果脑内干扰素刺激基因未对其进行阻断,这些病毒就能在脑细胞中感染、复制和传播。水疱性口炎病毒(VSV)作为疫苗载体和溶瘤病毒都显示出相当大的前景。VSV最大的局限性在于它具有高度嗜神经性,在脑内可能致死。这种嗜神经性主要可归因于VSV G糖蛋白。在此,我们测试了4种VSV嵌合病毒,它们分别含有来自尼帕病毒、基孔肯雅病毒和流感病毒的糖蛋白基因以及来自塞姆利基森林病毒的非结构基因。四种中的两种,VSVΔG-CHIKV和VLV,表现出明显减弱的嗜神经性,在健康成年小鼠脑中是安全的。VSVΔG-H5N1在成年脑中是安全的,但在幼龄脑中是致死的。VSVΔG尼帕F+G比野生型VSV更具嗜神经性,在成年脑中引发快速致死反应。这些结果表明,虽然嵌合VSV显示出前景,但每种都必须通过鼻内和颅内给药进行测试,以确保不存在致死性嗜神经性。